Caribou Biosciences reported that its allogeneic CAR‑T candidate induced high remission rates in advanced B‑cell lymphoma, claiming outcomes comparable to autologous CAR‑T benchmarks. In a small study, vespa‑cel (formerly CB‑010) produced a reported 64% complete response rate and an 82% overall response rate, with roughly half of patients progression‑free at one year. Despite positive efficacy signals, Caribou said it needs to raise additional capital to advance development and scale manufacturing for an off‑the‑shelf model. The company argues that a successful off‑the‑shelf product could lower costs and expand access relative to bespoke CAR‑T, but investors and partners will scrutinize durability, manufacturing consistency, and safety. Operationally, Caribou must convert preliminary data into larger, controlled trials and secure manufacturing capacity; any funding delay or negative safety signal could stall momentum in the nascent allogeneic cell therapy field.